“In the past few decades, pharmaceutical innovation has largely been driven by a high-margin, low-volume sales model that is now increasingly under pressure. In the next few decades, the market will drive a shift to “frugal” innovation, characterised by a lower margin, larger volume model. CASMI will have a pivotal role in determining how to achieve this.”
Stephen MacMahon is founder and Principal Director of The George Institute for Global Health. He is also Professor of Medicine & James Martin Fellow at the University of Oxford and Professor of Cardiovascular Medicine at the University of Sydney. He is an international authority on the causes, prevention and treatment of cardiovascular diseases. His special interest is the management of chronic and complex conditions in resource-poor settings, particularly in the Asia-Pacific region. As Principal Director of The George Institute, Professor MacMahon is responsible for more than 300 staff at Institute research facilities in Australia, China, India and theUK. From these sites, research programs in cardiology, nephrology, neurology, musculoskeletal medicine, injury prevention and intensive care are coordinated across more than 40 countries worldwide.
In addition to his University and Institute appointments, Professor MacMahon holds several external appointments, including those as Chairman of the International Scientific Board of the UK BioBank. He has published several hundred scientific papers and delivered many invited lectures. For his work in the field of cardiovascular disease, he has received numerous awards, fellowships and honours. In 2012 he was appointed to the Fellowship of the Australian Academy of Science and the British Academy of Medical Sciences.